These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 2171608)

  • 1. Thyrotoxic Graves' disease with normal thyroidal technetium-99m pertechnetate uptake.
    Ikekubo K; Hino M; Ito H; Koh T; Ishihara T; Kurahachi H; Kasagi K; Hidaka A; Mori T
    Ann Nucl Med; 1990 Jul; 4(2):43-8. PubMed ID: 2171608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the factors associated with Tc-99m pertechnetate uptake in thyrotoxicosis and graves' disease.
    Kidokoro-Kunii Y; Emoto N; Cho K; Oikawa S
    J Nippon Med Sch; 2006 Feb; 73(1):10-7. PubMed ID: 16538017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutoff value of thyroid uptake of (99m)Tc-pertechnetate to discriminate between Graves' disease and painless thyroiditis: a single center retrospective study.
    Uchida T; Suzuki R; Kasai T; Onose H; Komiya K; Goto H; Takeno K; Ishii S; Sato J; Honda A; Kawano Y; Himuro M; Yamada E; Yamada T; Watada H
    Endocr J; 2016; 63(2):143-9. PubMed ID: 26581846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scintigraphic findings of the thyroid in euthyroid ophthalmic Graves' disease.
    Kasagi K; Hidaka A; Misaki T; Miyamoto S; Takeuchi R; Sakahara H; Sasayama S; Iida Y; Konishi J
    J Nucl Med; 1994 May; 35(5):811-7. PubMed ID: 8176463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serial occurrence of two types of postpartum thyroid disorders. Usefulness of Tc-99m pertechnetate uptake.
    Misaki T; Miyamoto S; Kasagi K; Mori T; Konishi J
    Clin Nucl Med; 1996 Jun; 21(6):460-2. PubMed ID: 8744180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High pre-therapy [99mTc]pertechnetate thyroid uptake, thyroid size and thyrostatic drugs: predictive factors of failure in [131I]iodide therapy in Graves' disease.
    Zantut-Wittmann DE; Ramos CD; Santos AO; Lima MM; Panzan AD; Facuri FV; Etchebehere EC; Lima MC; Tambascia MA; Camargo EE
    Nucl Med Commun; 2005 Nov; 26(11):957-63. PubMed ID: 16208172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitive thyroid-stimulating antibody assay with high concentrations of polyethylene glycol for the diagnosis of Graves' disease.
    Takasu N; Kamijo K; Sato Y; Yoshimura H; Nagata A; Ochi Y
    Clin Exp Pharmacol Physiol; 2004; 31(5-6):314-9. PubMed ID: 15191404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prediction of remission in Graves' disease after thionamide therapy by technetium-99m early uptake].
    Misaki T; Dokoh S; Koh T; Shimbo S; Hidaka A; Iida Y; Kasagi K; Konishi J
    Kaku Igaku; 1991 Feb; 28(2):157-61. PubMed ID: 1711131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves' disease.
    Ota H; Amino N; Morita S; Kobayashi K; Kubota S; Fukata S; Kamiyama N; Miyauchi A
    Clin Endocrinol (Oxf); 2007 Jul; 67(1):41-5. PubMed ID: 17437515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical studies on abnormal thyroid stimulators in patients with Graves' disease. I. A sensitive assay for thyroid-stimulating antibodies using cultured porcine thyroid cells and polyethylene glycol precipitation of serum].
    Uno C; Nishikawa M
    Nihon Naibunpi Gakkai Zasshi; 1988 Mar; 64(3):193-205. PubMed ID: 2899523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pertechnetate thyroid uptake is not always suppressed in patients with subacute thyroiditis.
    Shigemasa C; Teshima S; Taniguchi S; Ueta Y; Mitani Y; Yoshida A
    Clin Nucl Med; 1997 Feb; 22(2):109-14. PubMed ID: 9031769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroid blood flow and uptake of technetium-99m pertechnetate in Graves' disease.
    Sekulić V; Rajić M; Vlajković M; Ilić S; Bogićević M; Antić S; Dimić D
    Hell J Nucl Med; 2006; 9(3):173-6. PubMed ID: 17160158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simple and practical parameters for differentiation between destruction-induced thyrotoxicosis and Graves' thyrotoxicosis.
    Izumi Y; Hidaka Y; Tada H; Takano T; Kashiwai T; Tatsumi KI; Ichihara K; Amino N
    Clin Endocrinol (Oxf); 2002 Jul; 57(1):51-8. PubMed ID: 12100069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between peak systolic velocity of the inferior thyroid artery and technetium-99m pertechnetate thyroid uptake in differentiating Graves' disease from thyroiditis.
    Malik SA; Choh NA; Misgar RA; Khan SH; Shah ZA; Rather TA; Shehjar F; Laway BA
    Arch Endocrinol Metab; 2019; 63(5):495-500. PubMed ID: 31482952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological findings and thyroid function of untreated Graves' disease patients with undetectable TSH-binding inhibitor immunoglobulin.
    Mukuta T; Tamai H; Oshima A; Morita T; Matsubayashi S; Fukata S; Kuma K
    Clin Endocrinol (Oxf); 1994 Feb; 40(2):215-9. PubMed ID: 7907955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical studies on abnormal thyroid stimulators in patients with Graves' disease. II. Clinical significance of measuring TSAb and TBII in patients with euthyroid Graves' disease and patients with hyperthyroid Graves' disease during antithyroid drug treatment].
    Uno C; Nishikawa M
    Nihon Naibunpi Gakkai Zasshi; 1988 Mar; 64(3):206-15. PubMed ID: 2456230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of remission in Graves' disease treated with long-term carbimazole therapy: evaluation of technetium-99m thyroid uptake and TSH concentrations as prognostic indicators.
    Prakash R
    Eur J Nucl Med; 1996 Feb; 23(2):118-22. PubMed ID: 8925844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graves' disease: thyroid function and immunologic activity.
    Gossage AA; Crawley JC; Copping S; Hinge D; Himsworth RL
    J Nucl Med; 1982 Nov; 23(11):973-7. PubMed ID: 6290623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
    Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
    J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
    Sato K; Yamazaki K; Yamada E; Kanaji Y; Miura M; Obara T
    Thyroid; 1999 Oct; 9(10):979-88. PubMed ID: 10560951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.